Curis (CRIS) Stock Forecast & Price Target

Curis is supported primarily by a strengthening emavusertib dataset in PCNSL, where emavusertib plus ibrutinib delivered a 100% ORR in five of five evaluable BTKi-naïve patients and 33% ORR in BTKi-experienced patients across 30 evaluable patients, improving the registrational case for accelerated approval in the U.S. and Conditional Marketing Authorization in Europe. Management’s plan to expand across BTKi-used NHL subtypes and the dual NF-κB blockade rationale add strategic upside, while the December 2026 TakeAim CLL interim in 5 to 10 patients offers a key test of deeper responses and MRD clearance potential. The main financial risk is execution timing because 2Q26 results indicate the value is increasingly dependent on access to additional capital, but the current clinical momentum and active site/patient enrollment are encouraging.

Curis is fundamentally challenged by a highly concentrated, clinical-stage valuation that depends heavily on emavusertib, with 56% of value tied to PCNSL, 24% to AML/MDS, and 20% to CLL, leaving the shares vulnerable to any missed or inconclusive readout. The company also faces financing strain, as further AML/MDS development is explicitly contingent on additional funding, while PCNSL timing has already been pushed to 2029 from 2028 to allow full enrollment by 2027 and durability follow-up. Without reported median DoR, PFS, confirmation status, or safety update, the data remain insufficient to de-risk the program, making the investment case speculative and fragile.